F2-Isoprostanes as biomarkers of lipid peroxidation in patients with chronic renal failure

BioFactors

Volumn 24, Issue 1-4, 2005, Pages 201-208

  Wiswedel, Ingrid ^a   Hirsch, Daniela ^a   Carluccio, Francesco ^b   Hampl, Hannelore ^c   Siems, Werner ^d  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b I Veris Delli Ponti Hospital   (Italy)

^c HUMBOLDT UNIVERSITY   (Germany)

^d Loges School of Physical Medicine   (Germany)

Author keywords

Antioxidants; Chronic renal failure; F2 isoprostanes; Hemodialysis patients; Inflammation; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; CHOLESTEROL DERIVATIVE; HYDROCARBON; ISOPROSTANE DERIVATIVE; LIPID HYDROPEROXIDE; MALONALDEHYDE; OXIDIZING AGENT; PROSTAGLANDIN F2 ALPHA;

ARTICLE; ATHEROGENESIS; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOTHELIUM LESION; ESTERIFICATION; GAS CHROMATOGRAPHY; HEMODIALYSIS; HEMOLYSIS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KIDNEY FAILURE; LEUKOCYTE ACTIVATION; LIPID PEROXIDATION; MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; BLOOD; INFLAMMATION; MASS FRAGMENTOGRAPHY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; F2-ISOPROSTANES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; OXIDATIVE STRESS; RENAL DIALYSIS; RISK FACTORS;

EID: 28644451178     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520240124     Document Type: Article

References (40)

1. H. Trachtman, D. Wilson and P.S. Rao, The role of oxygen-free radicals in the development of chronic renal failure, Life Sci 50 (1992), 1877-1883.
2. J. Westhuyzen, C.E. Adams and S.J. Fleming, Evidence for oxidative stress during in vitro dialysis, Nephron 70 (1995), 49-54.
3. W. Siems, S. Quast, F. Carluccio, I. Wiswedel, D. Hirsch, W. Augustin, H. Hampl, M. Riehle and O. Sommerburg, Oxidative stress in chronic renal failure as a cardiovascular risk factor, Clin Nephrol 58(Suppl 1) (2002), 12-19.
4. C. Cavdar, T. Camsari, I. Semin, S. Gonenc and O. Acikgoz, Lipid peroxidation and antioxidant activity in chronic hemodialysis patients with recombinant human erythropoietin, Scand J Urol Nephrol 31 (1997), 371-375.
5. M.C. Delmas Beauvieux, C. Combe and E. Peuchant, Evaluation of red blood cell lipid peroxidation in hemodialyzed patients during erythropoietin therapy supplemented or not with iron, Nephron 31 (1995), 406-410.
6. C.M. Loughrey, I.S. Young, J.H. Lightbody, D. McMaster, P.T. McNameee and E.R. Trimble, Oxidative stress in hemodialysis, Q J Meid 87 (1994), 679-683.
7. E. Peuchant, M.C. Delmas-Beauvieux, L. Dubourg, M.J. Thomas, A. Perromat, M. Aparicio, M. Clerc and C. Combe, Antioxidant effects of a supplemented very low protein diet in chronic renal failure. Free Radic Biol Med 22 (1997), 313-320.
8. O. Sommerburg, T. Grune, H. Hampl, E. Riedel, F.J.M.G. van Kuijk, J.H.H. Ehrich and W.G. Siems, Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 13 (1997), 2583-2587.
9. K. Ludat, O. Sommerburg, T. Grune, W.G. Siems, E. Riedel and H. Hampl, Oxidation parameters in complete correction of renal anemia, Clinical Nephrology 53(Suppl 1) (2000), 30-S35.
10. W. Siems, F. Carluccio, T. Grune, M. Jakstadt, S. Quast, H. Hampl and O. Sommerburg, Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia, Clin Nephrol 58(Suppl 1) (2002), 20-25.
11. I. Ceballos-Picot, V. Witko-Sarsat, M. Merad-Boudia, A.T. Nguyen, M. Thévenin, M.C. Jaudon, H. Higraff, C. Verger, P. Jungers and B. Descamps-Latscha, Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure, Free Radic Biol Med 21 (1996), 845-853.
12. E. Peuchant, M.-C. Delmas-Beauvieux, L. Dubourg, M.-J. Thomas, A. Perromat, M. Aparicio, M. Clerc and C. Combe, Antioxidant effects of a supplemented very low protein diet in chronic renal failure, Free Radic Biol Med 22 (1997), 313-320.
13. H. Esterbauer, R.J. Schaur and H. Zollner, Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes, Free Radic Biol Med 11 (1991), 81-128.
14. W. Siems, S.J. Hapner and F.J.G.M. van Kuijk, 4-Hydroxynonenal inhibits Na+-K+-ATPase, Free Radic Biol Med 20 (1996), 215-223.
15. K. Uchida, M. Shiraishi, Y. Naito, Y. Torii, Y. Nakamura and T. Osawa, Activation of stress signaling pathway by the end product of lipid peroxidation. 4-Hydroxynonenal is a potential inducer of intracellular peroxide production, J Biol Chem 274 (1999), 2234-2242.
16. J. Ruef, M. Moser, C. Bode, W. Kuebler and M.S. Runge, 4-Hydroxynonenal induces apoptosis, NF-κB-activation and formation of 8-isoprostane in vascular smooth muscle cells, Basic Res Cardiol 96 (2001), 143-150.
17. J.D. Morrow, W.E. Zackert, D.S. van der Ende, E.E. Reich, E.S. Terry, B. Cox, S.C. Sanchez, T.J. Montine and L.J. Roberts, Qantification of isoprostanes as indicators of oxidant stress in vivo, in: Handbook of Antioxidants, 2nd edition E. Cadenas and L. Packer, eds, Marcel Dekker, Inc., New York, Basel, 2002, pp. 57-74.
18. I. Wiswedel, D. Hirsch, S. Kropf, M. Gruening, E. Pfister, T. Schewe and H. Sies, Flavanol-rich cocoa drink lowers plasma F2-isoprostane concentrations in humans, Free Radic Biol Med 37 (2004), 411-421.
19. 2 receptors, J Clin Invest 90 (1992), 136-141.
20. 2-isoprostane receptors on rat vascular smooth muscle cells, Am J Physiol 264 (1993), 1619-1624.
21. 2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist, Prostaglandins 44 (1992), 155-163.
22. M.L. Wratten, C. Tretta, F. Ursini and A. Sevanian, Oxidant stress in hemodialysis: prevention and treatment strategies, Kidney Int 76(Suppl) (2000), 126-132.
23. 2-isoprostanes as an index of oxidative stress in vivo, Free Radic Biol Med 28 (2000), 505-513.
24. 2-Isoprostane serum concentrations in patients with chronic renal failure in relation to inflammation and renal anemia, 2005, submitted.
25. 2-isoprostanes before and after hemodialysis in end-stage renal disease patients, Prostaglandins Leukot Essent Fatty Acids 70 (2004), 475-478.
26. B. Ferraro, F. Galli, B. Frei, E. Kingdon, F. Canestrari, C. Rice-Evans, U. Buoncristiani, A. Davenport and K.P. Moore, Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients, Kidney Int 63 (2003), 2207-2213.
27. M. Danielski, T.A. Ikizler, E. McMonagle, J.C. Kane, L. Pupim, J. Morrow and J. Himmelfarb, Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy, Am J Kidney Dis 42 (2003), 286-294.
28. P.S. Lim, Y.M. Chang, L.M. Thien, N.P. Wang, C.C. Yang, T.T. Chen and W.M. Hsu, 8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients, Blood Purification 20 (2002), 537-542.
29. 2-isoprostane levels are elevated in chronic hemodialysis patients, Clin Nephrol 58 (2002), 190-197.
30. 2-isoprostanes in patients on long-term hemodialysis, Kidney Int 59 (2001), 1960-1966.
31. 2-isoprostanes following intravenous iron infusion in patients on hemodialysis, Kidney Int 60 (2001), 1525-1531.
32. J. Zimmermann, S. Herrlinger, A. Pruy et al., Inflammation enhances cardiovascular risk and mortality in hemodialysis patients, Kidney Int 55 (1999), 648-658.
33. K. Hensley, K.A. Robinson, S.P. Gabbita et al., Reactive oxygen species, cell signalling, and cell injury, Free Radic Biol Med 28 (2000), 1456-1462.
34. T. Nguyen-Khoa, Z. A. Massy, J.P. de Brandt et al., Oxidative stress and hemodialysis; role of inflammation and duration of dialysis treatment, Nephrol Dial Transplant 16 (2001), 335-340.
35. L.B. Pupim, J. Himmelfarb, E. McMonagle, Y. Shyr and T. A. Ikizler, Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress, Kidney Int 66 (2004), 2093-2094.
36. C. Wanner and T. Metzger, C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients, Nephrol Dial Transplant 17 (2002), 29-32, 39-40.
37. S. Okhawa, T. Yoneyama, K. Shimoi, Y. Mrruyama and H. Kumagai, Pro-oxidative effect of alpha-tocopherol in the oxidation of LDL isolated from co-antioxidant-depleted non-diabetic hemodialysis patients, Atherosclerosis 176 (2004), 411-418.
38. P. Jackson, C.M. Loughrey, J.H. Lightbody et al., Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure, Clin Chem 41 (1995), 1135-1138.
39. M. Boaz, S. Smetana , T. Weinstein, Z. Matas, U. Gafter, A. Iaina, A. Knecht, Y. Weissgarten, D. Brunner, M. Fainaru and M.S. Green, Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial, Lancet 356 (2000), 1213-1218.
40. M. Tepel, M. van der Giet, M. Statz, J. Jankowski and W. Zidek, The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial, Circulation 107 (2003), 992-995.